Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 12/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | TNK2 | Q07912 | 6/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3297099 | 0.93 | IGF1R (0.58) | IGF1RJAK2JAK3TNK2NTRK1 | |
| SCHEMBL3299047 | 0.91 | IGF1R (0.54) | IGF1RJAK2JAK3TNK2NTRK1 | |
| SCHEMBL3294480 | 0.91 | IGF1R (0.58) | IGF1RJAK2JAK3TNK2NTRK1 | |
| SCHEMBL3301889 | 0.87 | IGF1R (0.54) | IGF1RJAK2JAK3TNK2NTRK1 | |
| SCHEMBL3296321 | 0.86 | IGF1R (0.72) | IGF1RTNK2 | |
| SCHEMBL3299932 | 0.86 | IGF1R (0.54) | IGF1RJAK2JAK3TNK2 | |
| SCHEMBL3297945 | 0.86 | IGF1R (0.57) | IGF1RJAK2JAK3TNK2NTRK1 | |
| SCHEMBL3296911 | 0.85 | IGF1R (0.60) | IGF1RTNK2 | |
| SCHEMBL3299467 | 0.85 | IGF1R (0.62) | IGF1RTNK2 | |
| SCHEMBL3303452 | 0.84 | IGF1R (0.55) | IGF1RJAK2JAK3TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741324-B2 | Imidazotriazines as protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | claimed |
| EP-1781660-A1 | IMIDAZOPYRAZINE AS TYROSINE KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2007-05-09 | — | — | EP | claimed |
| WO-2006012422-A1 | IMIDAZOPYRAZINE AS TYROSINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-20060019957-A1 | Imidazotriazines as protein kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2006-01-26 | — | — | US | claimed |
| US-7741324-B2 | Imidazotriazines as protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1781660-A1 | IMIDAZOPYRAZINE AS TYROSINE KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006012422-A1 | IMIDAZOPYRAZINE AS TYROSINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20060019957-A1 | Imidazotriazines as protein kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019957-A1 | Imidazotriazines as protein kinase inhibitors | IGF1R, IRS1, INSR | IGF1R 1/4885JAK2 17/4885JAK3 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.